Opinion on Pharmaceutical Manufacturers in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Novartis's novel bronchodilator paves way for potent COPD combinations

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).

Published By Datamonitor
09 Jun 2005
CommentWire
CommentWire

Schering-Plough: soft impact for extended Temodal approval

Schering-Plough's Temodal has been approved in the EU for the first-line treatment of glioblastoma multiforme (GBM) in combination with radiotherapy, following US approval in March. However, as the drug has already been in use off-label for previously-untreated GBM patients, there is unlikely to be a substantial surge in sales of Temodal in the EU.

Published By Datamonitor
14 Jun 2005
CommentWire
CommentWire

OSI / Roche / Genentech: European approval would confirm Tarceva's lead

An EMEA committee has recommended approval of Tarceva in an advanced non-small cell lung cancer (NSCLC) indication. If granted, the approval should make Tarceva the leading drug of its kind in the lung cancer market, as well as strengthening OSI, Genentech and Roche's positions in oncology.

Published By Datamonitor
27 Jun 2005
CommentWire
CommentWire

Novartis: generic dominance may take Eons to realize

Following reports that Eon Labs shareholders believed the agreed price was too low, Novartis has extended its tender offer to acquire the remaining stake in the company. However, the delay, alongside other happenings in the generics market, could spark a wave of consolidation, suggesting Novartis's generics business has further challenges to come.

Published By Datamonitor
06 Jul 2005
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
Expert View
Expert View

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor
02 Aug 2005
ResearchWire
ResearchWire

Functional drinks: nutraceuticals keep the French market moving

Published By Datamonitor
11 Aug 2005
CommentWire
CommentWire

Bayer: the power of three

After achieving encouraging phase II results, Bayer has revealed that it intends to seek regulatory approval for BAY-597939 by the end of 2007 and has entered talks with potential development and marketing partners. However, Bayer's best laid plans for the drug candidate may not be enough to counter the challenge of Boehringer Ingelheim's rival pipeline offering.

Published By Datamonitor
11 Aug 2005
CommentWire
CommentWire

Novartis: premium price for Chiron still to come

Chiron has snubbed Novartis' offer to acquire the remaining shares of the company that it does not already own, calling the offer "inadequate". Chiron no doubt wants to hold out for a better offer, which is a wise move since, as Novartis will be the key benefactor from the takeover, the Swiss company is likely to significantly increase its bid.

Published By Datamonitor
07 Sep 2005
CommentWire
CommentWire

GlaxoSmithKline: a hearty triumph for Arixtra

GlaxoSmithKline looks set to enhance its thrombosis market position after study results suggested Arixtra could become the treatment of choice in acute coronary syndrome. In the study Arixtra demonstrated equivalent efficacy to Sanofi-Aventis' Lovenox but with significantly less bleeding. These results are a clear fillip for GSK, from which a considerable marketing push for Arixtra is expected.

Published By Datamonitor
07 Sep 2005

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.